Superior HypogastrIc plExus bLock During Laparoscopic Colorectal Cancer Surgery

NCT07579780 | Recruiting

• 1 other identifier: E2025271
• Study Type: interventional
• Target: 170
• Locations: 1 country
• Sites: 1

Brief Summary

This trial seeks to assess the efficacy of a superior hypogastric plexus block for early quality of recovery after laparoscopic colorectal cancer surgery.

Conditions

Colorectal Cancer (Diagnosis); Laparoscopic Surgery; Superior Hypogastric Plexus Block

Keywords

Colorectal Cancer; laparoscopic surgery; superior hypogastric plexus block; Quality of recovery

Outcome Measures

Primary Outcomes (1)

• Quality of recovery

  The Quality of recovery (QoR) 15, ranging from 0 (the worst) to 150 (the best), is a patient-reported outcome questionnaire that measures the quality of recovery after surgery.

  Up to postoperative day 2

Secondary Outcomes (7)

• Postoperative Pain Scores

  Up to postoperative day 2

• Postoperative Opioid Use

  Up to postoperative day 2

• The Brief Pain Inventory (BPI)

  Up to postoperative day 90

• The McGill Pain Questionnaire

  Up to postoperative day 90

• Length of stay in post-anesthesia care unit (PACU) area

  Postoperative day 1

Other Outcomes (1)

• Incidence of Adverse events

  Intraoperative (During block performance)

Study Arms (2)

Nerve block

EXPERIMENTAL

The superior hypogastric plexus block in this group will contain 20 mL of 0.75% ropivacaine hydrochloride.

Procedure: Superior hypogastric plexus block

Placebo block

PLACEBO COMPARATOR

The superior hypogastric plexus block in this group will contain 20 mL of 0.9% normal saline.

Procedure: Superior hypogastric plexus block

Interventions

Superior hypogastric plexus block PROCEDURE

After establishing pneumoperitoneum in laparoscopic colorectal cancer surgery, the superior hypogastric plexus block will be performed on all patients. The block will contain 20 mL of 0.75% ropivacaine hydrochloride or 0.9% normal saline. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.

Nerve block; Placebo block

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Able to provide informed consent.
• Undergoing elective laparoscopic radical resection for colorectal cancer.
• American Society of Anesthesiologists Physical Status (ASA) class I-III.

You may not qualify if:

• Allergy to block medication (s).
• Coagulation dysfunction.
• Local or systemic infection.
• Unable to cooperate with the completion of the study protocol.

Sponsors & Collaborators

• Sixth Affiliated Hospital, Sun Yat-sen University: lead

Study Sites (1)

The Sixth Affiliated Hospital of Sun Yet-set University

Guangzhou, Guangdong, 510000, China

RECRUITING

MeSH Terms

Conditions

Colorectal Neoplasms; Disease

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Mengying Ding

CONTACT

+86-15170375679; 15170375679@163.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: April 28, 2026
• First Posted: May 12, 2026
• Study Start: December 15, 2025
• Primary Completion (Estimated): December 18, 2026
• Study Completion (Estimated): February 18, 2027
• Last Updated: May 12, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)